Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INB-200
- Development stage
- Unknown
- Lead developer
- IN8bio
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
INB-200 is a genetically modified autologous gamma-delta T cell therapy developed for the treatment of newly diagnosed glioblastoma (GBM) and other solid tumors. It is the first genetically engineered gamma-delta T cell therapy administered to patients with solid tumors. The product uses gene modification to confer resistance to alkylating chemotherapy agents such as temozolomide (TMZ), allowing these immune cells to persist and function during concurrent chemotherapy. This enables a synergistic approach where the engineered gamma-delta T cells can recognize and kill cancer cells even in the presence of lymphodepleting chemotherapeutic agents. INB-200 is currently being evaluated in Phase 1 clinical trials for GBM[1][2][3][4][5][7].
- Brand names
- DeltEx
- Other names
- CliniMACS Alpha Beta T-Cell Depletion SystemCliniMACS-Prodigy
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on INB-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INB-200.